TELA Stock Overview
A commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient’s anatomy. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
TELA Bio, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$2.85 |
| 52 Week High | US$7.84 |
| 52 Week Low | US$2.30 |
| Beta | 1.0 |
| 1 Month Change | -1.72% |
| 3 Month Change | 10.04% |
| 1 Year Change | -55.40% |
| 3 Year Change | -77.20% |
| 5 Year Change | -77.47% |
| Change since IPO | -78.65% |
Recent News & Updates
Even With A 27% Surge, Cautious Investors Are Not Rewarding TELA Bio, Inc.'s (NASDAQ:TELA) Performance Completely
Nov 09
Not Many Are Piling Into TELA Bio, Inc. (NASDAQ:TELA) Stock Yet As It Plummets 33%
Aug 19Recent updates
Even With A 27% Surge, Cautious Investors Are Not Rewarding TELA Bio, Inc.'s (NASDAQ:TELA) Performance Completely
Nov 09Not Many Are Piling Into TELA Bio, Inc. (NASDAQ:TELA) Stock Yet As It Plummets 33%
Aug 19Does TELA Bio (NASDAQ:TELA) Have A Healthy Balance Sheet?
Jul 03Shareholders May Be More Conservative With TELA Bio, Inc.'s (NASDAQ:TELA) CEO Compensation For Now
May 29TELA Bio, Inc. (NASDAQ:TELA) Soars 31% But It's A Story Of Risk Vs Reward
May 23Earnings Update: TELA Bio, Inc. (NASDAQ:TELA) Just Reported Its Annual Results And Analysts Are Updating Their Forecasts
Mar 24Many Still Looking Away From TELA Bio, Inc. (NASDAQ:TELA)
Mar 08TELA Bio (NASDAQ:TELA) Has Debt But No Earnings; Should You Worry?
Oct 07Getting In Cheap On TELA Bio, Inc. (NASDAQ:TELA) Might Be Difficult
Jul 31TELA Bio: Tailwinds In Hernia Repair Market And Promising Clinical Data To Drive Accelerating Adoption
Oct 02Tela Bio prices $32M common stock offering
Aug 16Is TELA Bio (NASDAQ:TELA) Using Debt Sensibly?
May 12TELA Bio - Follow Up With Management
Jan 14Our First Look At TELA Bio
Nov 04TELA Bio Plugging Away
Oct 25TELA Bio (TELA) Investor Presentation - Slideshow
May 26Shareholder Returns
| TELA | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | 2.9% | -1.5% | -2.4% |
| 1Y | -55.4% | 10.1% | 23.3% |
Return vs Industry: TELA underperformed the US Medical Equipment industry which returned 9% over the past year.
Return vs Market: TELA underperformed the US Market which returned 22.1% over the past year.
Price Volatility
| TELA volatility | |
|---|---|
| TELA Average Weekly Movement | 8.0% |
| Medical Equipment Industry Average Movement | 7.6% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 16.8% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: TELA has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: TELA's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2012 | 227 | Antony Koblish | www.telabio.com |
TELA Bio, Inc., a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient’s anatomy. The company provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix products to address the unmet needs in plastic and reconstructive surgery, as well as OviTex for Laparoscopic and Robotic Procedures, a sterile reinforced tissue matrix derived from ovine rumen with polypropylene fiber intended to be used in laparoscopic and robotic-assisted hernia surgical repairs. It markets its products through a single direct sales force, principally in the United States.
TELA Bio, Inc. Fundamentals Summary
| TELA fundamental statistics | |
|---|---|
| Market cap | US$110.29m |
| Earnings (TTM) | -US$41.52m |
| Revenue (TTM) | US$68.65m |
1.6x
P/S Ratio-2.7x
P/E RatioIs TELA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| TELA income statement (TTM) | |
|---|---|
| Revenue | US$68.65m |
| Cost of Revenue | US$21.38m |
| Gross Profit | US$47.27m |
| Other Expenses | US$88.79m |
| Earnings | -US$41.52m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.05 |
| Gross Margin | 68.86% |
| Net Profit Margin | -60.49% |
| Debt/Equity Ratio | -653.2% |
How did TELA perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/20 16:23 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
TELA Bio, Inc. is covered by 8 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Kyle Rose | Canaccord Genuity |
| William Plovanic | Canaccord Genuity |
| Caitlin Cronin | Canaccord Genuity |